Perspective on type 2 diabetes mellitus in the Instituto Mexicano del Seguro Social
Main Article Content
Keywords
Diabetes mellitus, Diabetes complications, Patient education as topic
Abstract
The Instituto Mexicano del Seguro Social —always sensitive to the needs of health of the beneficiary population and to the demographic and epidemiological changes of the society— has developed and implemented DiabetIMSS, a program of attention to the diabetic patient. DiabetIMSS organizes care processes based on the needs and values of the patients, through simultaneous activities of individual consultation and group meetings granted by the multidisciplinary health team. These actions and activities are focused to affect patients’ lifestyles positively. Through a plan of nutrition, physical activity, self-care and monitoring, this program increases the interaction between patients, by having an exchange of successful experiences about diabetes control. DiabetIMSS was created with the purpose that the patients achieve the metabolic control and identify complications early on, with the perspective of timely intervention that is reflected in the decrease of the catastrophic effects that causes the disease, both for patient’s life expectancy and the quality of care provided by the Institute.
References
Wild S, Roglic G, Green A, Sicree R. Global prevalence of diabetes: estimates for the year 2000 and
projections for 2030. Diabetes Care. 2004;27:1047-53.
Organización Panamericana de la Salud. Estrategia regional y plan de acción para un enfoque integrado sobre la prevención y el control de las enfermedades crónicas. Washington: OPS; 2007.
Arredondo A, Zúñiga A. Economic consequences of epidemiological changes in middle income countries: the Mexican case. Diabetes Care. 2004;27:104-9.
Instituto Mexicano del Seguro Social. Informe al Ejecutivo Federal y al Congreso de la Unión sobre la situación financiera y los riesgos del
Instituto Mexicano del Seguro Social 2009-2010.
México: IMSS; 2010.
Organización Mundial de la Salud. Diabetes. Nota descriptiva 312. Septiembre 2012.
Olaiz G, Rojas R, Aguilar C, Rauda J, Villalpando S. Diabetes mellitus en adultos mexicanos. Resultados de la Encuesta Nacional de Salud 2000. Salud Pública Mex. 2007;49 supl 3:S331-7.
Barquera I, Campos N, Hernández B, Flores M, Durazo A, Kanter R, et al. Obesity and central adiposity in Mexican adults: results from the Mexican National Health and Nutrition Survey 2006. Salud Pública Mex. 2009;51 supl 4:S595-603.
Escobedo J, Buitrón LV, Velasco MF, Ramírez JC, Hernández R, Macchia A, et al. High prevalence of diabetes and impaired fasting glucose in urban Latin American: the CARMELA Study. Diabetes Med. 2009;26:864-71.
Gutiérrez-Trujillo G, Flores-Huerta S, Fernández-Gárate I, Martínez-Montañez O, Velasco-Murillo V, Fernández-Cantón S, et al. Estrategia de prestación y evaluación de servicios preventivos. Rev Med Inst Mex Seguro Soc. 2006;44 supl 1:S3-21.
Méndez D, Méndez B, Tapia-Yáñez JF, Muñoz-Montes T, Aguilar-Sánchez AL. Epidemiología de la insuficiencia renal en México. Dial Traspl. 2010;31(1):7-11.
Rodríguez-Ábrego G, Escobedo-de la Peña J, Zurita B, Ramírez TJ. Muerte prematura y discapacidad en los derechohabientes del Instituto Mexicano del Seguro Social. Salud Pública Mex. 2007;49:132-43.
Rhee SY, Woo JT. The prediabetic period: review of clinical aspects. Diabetes Metab J. 2011;35:107-16.
Gerstein H, Santaguida P, Raina P, Morrison K, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diab Res Clin Pract. 2007;78:305-12.
American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care. 2012;35 Suppl 1:S11-63.
Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease. A systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310-7.
Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucosa and impaired glucosa tolerance: im-
plications for care. Diabetes Care. 2007;30:753-9.
Tuomilehto J. Counterpoint. Evidence based
prevention of type 2 diabetes: the power of lifestyle management. Diabetes Care. 2007;30:435-8.
Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. Drug therapy to delay or prevent type 2 diabetes: a systematic review. Diabetes Care. 2005;28:736-44.
The Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care. 2003;26:977-80.
The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165-71.
Aguilar C, Gómez- Pérez F. La Declaración de Acapulco: propuesta para reducir la incidencia de la diabetes en México. Rev Inv Clin. 2006;58(1):71-7.
Herman W, Hoerger T, Brandle M, Hicks K, Sorensen S, Zhang P, et al.; for the Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323‑32.
Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, et al. Cost effectiveness of screening for prediabetes among overweight and obese US adults. Diabetes Care. 2007;30(11):2874-9.
Gil-Velázquez L, Sil-Acosta M, Domínguez SE, Torres-Arreola LP. Guía de práctica clínica. Diagnóstico y tratamiento de la diabetes mellitus tipo 2. Disponible en http://www.imss.gob.mx/profesionales/guiasclinicas/Documents/000GER_DiabetesmMellitus.pdf
Gamiochipi M, Haua NK, Valdez GL, Vázquez EF, Salinas MA, Wacher RN, et. al. Programa de educación en diabetes. México: Dirección de Prestaciones Médicas, IMSS; 2009. p. 1-129.
Gamiochipi M, Haua NK, Valdez GL, Vázquez EF, Salinas MA, Wacher RN, et. al. Manual del aplicador del módulo DiabetIMSS. México: Dirección de Prestaciones Médicas, IMSS; 2009. p. 1-182.
Francis T, Pellathy T, Ramon L, Torres J.
Confronting the crisis of chronic conditions in Latin America. Healthc Perspect Healthc. 2012;1:6-11.
American Association of Clinical Endocrinologists. Diabetes care plan guidelines. Endocr Pract. 2011;17(Suppl 2):1-53.
Ullrich, W, Marschall, U, Graf C. Versorgungsmerkmale des Diabetes mellitus in Disease-Management-Programmen. Ein Vergleich von in die DMP eingeschriebenen und nichteingeschriebenen Versicherten mit Diabetes. Diabetes Stoffwechsel Herz. 2007;16(6):407-14.
Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al. Effectiveness of the diabetes education and self-management for ongoing and newly diagnosed (DESMOND)
programme for people with newly diagnosed type 2 diabetes: cluster randomized controlled trial. BMJ. 2008;336(7642):491-5.
Comité de Educación, DOTA (Declaration of the Americas). Normas para el desarrollo de programas de educación sobre la diabetes en América. Rev Panam Salud Publica/Pan Am J Public Health. 2001;10(5):349-53.
Federación Internacional de Diabetes. Currículo internacional para la educación diabética de profesionales sanitarios. Federación Internacional de Diabetes.; 2008. p. 3-112.
Ministerio de Sanidad y Consumo. Guía de práctica clínica sobre diabetes tipo 2. España: Ministerio de Sanidad y Consumo; 2008.
Canadian Diabetes Association. 2008 Clinical practice guidelines for the prevention and management of diabetes in Canada. Disponible en http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf
Instituto Mexicano del Seguro Social. Guía de práctica clínica. Prevención, diagnóstico y tratamiento de la enfermedad renal crónica temprana. México: IMSS; 2009.
Secretaría de Salud. Guía de práctica clínica. Diagnóstico y tratamiento de la enfermedad arterial periférica. México: Secretaría de Salud; 2009.